Jordana Kate Schmier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4627853/publications.pdf

Version: 2024-02-01

117619 64791 6,456 97 34 79 citations h-index papers

g-index 97 97 97 7767 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Economic Burden of Periprosthetic Joint Infection in the United States. Journal of Arthroplasty, 2012, 27, 61-65.e1.	3.1	1,365
2	Infection Burden for Hip and Knee Arthroplasty in the United States. Journal of Arthroplasty, 2008, 23, 984-991.	3.1	851
3	Future Clinical and Economic Impact of Revision Total Hip and Knee Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2007, 89, 144-151.	3.0	464
4	The Burden of Influenza B: A Structured Literature Review. American Journal of Public Health, 2013, 103, e43-e51.	2.7	281
5	Complications, Mortality, and Costs for Outpatient and Short-Stay Total Knee Arthroplasty Patients in Comparison to Standard-Stay Patients. Journal of Arthroplasty, 2014, 29, 510-515.	3.1	245
6	Mortality Following the Diagnosis of a Vertebral Compression Fracture in the Medicare Population. Journal of Bone and Joint Surgery - Series A, 2008, 90, 1479-1486.	3.0	207
7	Patient recall and recall bias of health state and health status. Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 159-163.	1.4	183
8	Primary and Revision Arthroplasty Surgery Caseloads in the United States from 1990 to 2004. Journal of Arthroplasty, 2009, 24, 195-203.	3.1	179
9	Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data. Hypertension, 2006, 47, 1039-1048.	2.7	161
10	Cost of obesity in the workplace. Scandinavian Journal of Work, Environment and Health, 2006, 32, 5-11.	3.4	118
11	The Breathlessness, Cough, and Sputum Scale. Chest, 2003, 124, 2182-2191.	0.8	104
12	The impact of inadequately controlled asthma in urban children on quality of life and productivity. Annals of Allergy, Asthma and Immunology, 2007, 98, 245-251.	1.0	104
13	Health Care CBA and CEA from 1991 to 1996: An Updated Bibliography. Medical Care, 1998, 36, MS1-MS9.	2.4	102
14	A Stitch in Time: Improving Public Health Early Warning Systems for Extreme Weather Events. Epidemiologic Reviews, 2005, 27, 115-121.	3.5	87
15	Costâ€Effectiveness of Remote Cardiac Monitoring With the <scp>CardioMEMS</scp> Heart Failure System. Clinical Cardiology, 2017, 40, 430-436.	1.8	76
16	EVALUATION OF HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS OF ANEMIA AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS. Chest, 2005, 128, 257S.	0.8	74
17	EVALUATION OF COSTS FOR CYSTOID MACULAR EDEMA AMONG PATIENTS AFTER CATARACT SURGERY. Retina, 2007, 27, 621-628.	1.7	74
18	Allergic Rhinitis: A Potential Cause of Increased Asthma Medication Use, Costs, and Morbidity. Journal of Asthma, 2004, 41, 117-126.	1.7	72

#	Article	IF	CITATIONS
19	IMPACT OF VISUAL IMPAIRMENT ON USE OF CAREGIVING BY INDIVIDUALS WITH AGE-RELATED MACULAR DEGENERATION. Retina, 2006, 26, 1056-1062.	1.7	68
20	Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis. Annals of Allergy, Asthma and Immunology, 2004, 92, 201-207.	1.0	65
21	Willingness to Pay for Complete Symptom Relief of Gastroesophageal Reflux Disease. Archives of Internal Medicine, 2002, 162, 1361.	3.8	63
22	The Impact of Asthma on Health-Related Quality of Life. Journal of Asthma, 1998, 35, 585-597.	1.7	61
23	Perioperative outcomes, complications, and costs associated with lumbar spinal fusion in older patients with spinal stenosis and spondylolisthesis. Neurosurgical Focus, 2014, 36, E5.	2.3	60
24	The Economic Implications of Glaucoma. Pharmacoeconomics, 2007, 25, 287-308.	3.3	59
25	Anemia, costs and mortality in chronic obstructive pulmonary disease. Cost Effectiveness and Resource Allocation, 2006, 4, 17.	1.5	53
26	The Complexity of Treatment Adherence in Adults with Asthma: Challenges and Opportunities. Journal of Asthma, 1998, 35, 455-472.	1.7	46
27	The quality of life impact of acute exacerbations of chronic bronchitis (AECB): A literature review. Quality of Life Research, 2005, 14, 329-347.	3.1	46
28	Benefits And Costs Of Immunizing Children Against Influenza At School: An Economic Analysis Based On A Large-Cluster Controlled Clinical Trial. Health Affairs, 2008, 27, w96-w104.	5.2	46
29	Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease. Quality of Life Research, 2000, 9, 819-827.	3.1	44
30	Development and validation of a diseaseâ€specific treatment satisfaction questionnaire for gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2003, 18, 907-915.	3.7	44
31	Cost Effectiveness of Treatment of Parkinson??s Disease with Entacapone in the United States. Pharmacoeconomics, 2002, 20, 617-628.	3.3	37
32	Cost savings of reduced constipation rates attributed to increased dietary fiber intakes: a decision-analytic model. BMC Public Health, 2014, 14, 374.	2.9	37
33	Mortality, Cost, and Health Outcomes of Total Knee Arthroplasty in Medicare Patients. Journal of Arthroplasty, 2013, 28, 449-454.	3.1	36
34	Estimated hospital costs associated with preventable health care-associated infections if health care antiseptic products were unavailable. ClinicoEconomics and Outcomes Research, 2016, 8, 197.	1.9	35
35	Time and Economic Cost of Constipation Care in Nursing Homes. Journal of the American Medical Directors Association, 2002, 3, 215-223.	2.5	34
36	The Burden of Age-Related Macular Degeneration. Pharmacoeconomics, 2006, 24, 319-334.	3.3	34

#	Article	IF	CITATIONS
37	Impacts of a Smoking Cessation Benefit Among Employed Populations. Journal of Occupational and Environmental Medicine, 2007, 49, 11-21.	1.7	34
38	Trends in Annual Medicare Expenditures for Glaucoma Surgical Procedures From 1997 to 2006. JAMA Ophthalmology, 2009, 127, 900.	2.4	34
39	MEDICARE EXPENDITURES ASSOCIATED WITH DIABETES AND DIABETIC RETINOPATHY. Retina, 2009, 29, 199-206.	1.7	33
40	Cost-Effectiveness Analysis of Treatments for Vertebral Compression Fractures. Applied Health Economics and Health Policy, 2012, 10, 273-284.	2.1	33
41	Evaluation of Medicare Costs of Endophthalmitis among Patients after Cataract Surgery. Ophthalmology, 2007, 114, 1094-1099.	5.2	31
42	Health Economic Evaluation Modeling Shows Potential Health Care Cost Savings with Increased Conformance with Healthy Dietary Patterns among Adults in the United States. Journal of the Academy of Nutrition and Dietetics, 2019, 119, 599-616.	0.8	30
43	Utility Assessments of Opioid Treatment for Chronic Pain. Pain Medicine, 2002, 3, 218-230.	1.9	29
44	Meta-analysis of bacterial resistance to macrolides. Journal of Antimicrobial Chemotherapy, 2005, 55, 748-757.	3.0	28
45	Treatment costs of cystoid macular edema among patients following cataract surgery. Clinical Ophthalmology, 2016, 10, 477.	1.8	27
46	Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. Clinical Therapeutics, 2017, 39, 1600-1617.	2.5	27
47	The impact of climate change and aeroallergens on children's health. Allergy and Asthma Proceedings, 2009, 30, 229-237.	2.2	26
48	Practical applications of usability theory to electronic data collection for clinical trials. Contemporary Clinical Trials, 2005, 26, 376-385.	1.8	24
49	National Revision Burden for Lumbar Total Disc Replacement in the United States. Spine, 2010, 35, 690-696.	2.0	24
50	Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs. Clinical Ophthalmology, 2014, 8, 1097.	1.8	24
51	An updated estimate of costs of endophthalmitis following cataract surgery among Medicare patients: 2010–2014. Clinical Ophthalmology, 2016, Volume 10, 2121-2127.	1.8	24
52	Patterns and Costs Associated With Progression of Age-Related Macular Degeneration. American Journal of Ophthalmology, 2012, 154, 675-681.e1.	3.3	23
53	Comparative cost effectiveness of Coflex® interlaminar stabilization versus instrumented posterolateral lumbar fusion for the treatment of lumbar spinal stenosis and spondylolisthesis. ClinicoEconomics and Outcomes Research, 2014, 6, 125.	1.9	22
54	Mortality, Cost, and Downstream Disease of Total Hip Arthroplasty Patients in the Medicare Population. Journal of Arthroplasty, 2014, 29, 242-246.	3.1	22

#	Article	IF	CITATIONS
55	Efficacy, tolerability, and parent reported outcomes for cefdinir vs. high-dose amoxicillin/clavulanate oral suspension for acute otitis media in young children. Current Medical Research and Opinion, 2006, 22, 1839-1847.	1.9	21
56	First-year treatment patterns among new initiators of topical prostaglandin analogs. Current Medical Research and Opinion, 2009, 25, 851-858.	1.9	21
57	The Economic Impact of Acute Exacerbations of Chronic Bronchitis in the United States and Canada: A Literature Review. Journal of Managed Care Pharmacy, 2003, 9, 353-359.	2.2	19
58	Reduction in Oral Corticosteroid Use with Mometasone Furoate Dry Powder Inhaler Improves Health-Related Quality of Life in Patients with Severe Persistent Asthma. Journal of Asthma, 2003, 40, 383-393.	1.7	18
59	Resource utilization and costs of age-related macular degeneration. Health Care Financing Review, 2006, 27, 37-47.	1.8	18
60	Impact of visual impairment on service and device use by individuals with age-related macular degeneration (AMD). Disability and Rehabilitation, 2006, 28, 1331-1338.	1.8	17
61	Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs. Clinical Ophthalmology, 2010, 4, 1137.	1.8	16
62	A survey of standards and guidelines for cost-effectiveness analysis in health care*. American Heart Journal, 1999, 137, S53-S61.	2.7	14
63	Validation of the Daily Living Tasks Dependent on Vision (DLTV) Questionnaire in a U.S. Population with Age-Related Macular Degeneration. Ophthalmic Epidemiology, 2006, 13, 137-143.	1.7	14
64	Time and economic cost of constipation care in nursing homes. Journal of the American Medical Directors Association, 2002, 3, 215-23.	2.5	14
65	Cardiovascular Healthcare Cost Savings Associated with Increased Whole Grains Consumption among Adults in the United States. Nutrients, 2020, 12, 2323.	4.1	13
66	Characteristics of respondents with glaucoma and dry eye in a national panel survey. Clinical Ophthalmology, 2009, 3, 645.	1.8	12
67	Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management:a United States perspective. Current Medical Research and Opinion, 2007, 23, 2867-2875.	1.9	11
68	Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges. Pharmacoeconomics, 2016, 34, 259-272.	3.3	11
69	A Systematic Review of Cost-Effectiveness Analyses of Left Ventricular Assist Devices: Issues and Challenges. Applied Health Economics and Health Policy, 2019, 17, 35-46.	2.1	11
70	First-year treatment costs among new initiators of topical prostaglandin analogs. Clinical Ophthalmology, 2009, 3, 637.	1.8	10
71	Single food focus dietary guidance: lessons learned from an economic analysis of egg consumption. Cost Effectiveness and Resource Allocation, 2009, 7, 7.	1.5	10
72	Impact of visual impairment on service and device use by individuals with diabetic retinopathy. Disability and Rehabilitation, 2009, 31, 659-665.	1.8	10

#	Article	IF	Citations
73	Effect of battery longevity on costs and health outcomes associated with cardiac implantable electronic devices: a Markov model-based Monte Carlo simulation. Journal of Interventional Cardiac Electrophysiology, 2017, 50, 149-158.	1.3	10
74	Cost Effectiveness of Acute Imipramine Therapy versus Two Imipramine Maintenance Treatment Regimens for Panic Disorder. Pharmacoeconomics, 2000, 18, 383-391.	3.3	9
75	Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e185-e198.	0.4	9
76	Effects of Inhaled Corticosteroids on Mortality and Hospitalisation in Elderly Asthma and Chronic Obstructive Pulmonary Disease Patients. Drugs and Aging, 2005, 22, 717-729.	2.7	8
77	Health Care Costs and Savings Associated with Increased Dairy Consumption among Adults in the United States. Nutrients, 2020, 12, 233.	4.1	8
78	Travoprost versus latanoprost combinations in glaucoma:economic evaluation based on visual field deficit progression. Current Medical Research and Opinion, 2006, 22, 1737-1743.	1.9	7
79	First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008. Current Medical Research and Opinion, 2010, 26, 2769-2777.	1.9	6
80	A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. Journal of Medical Economics, 2016, 19, 1003-1010.	2.1	6
81	Medical Service Encounters and Payments Associated with Topical Adjunctive Therapy Use of Timolol for Glaucoma. Clinical Drug Investigation, 2012, 32, 835-842.	2.2	5
82	Cost Savings of Reduced Constipation Rates Attributed to Increased Dietary Fibre Intakes in Europe: A Decision-Analytic Model. Journal of Pharmacy and Nutrition Sciences (discontinued), 2015, 5, 14-23.	0.4	5
83	Patient-, Caregiver-, and Eye Care Professional-reported Burden of Geographic Atrophy Secondary to Age-related Macular Degeneration. American Journal of Ophthalmic Clinical Trials, 0, 2, 1.	0.0	4
84	First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results. Clinical Ophthalmology, 2010, 4, 437.	1.8	3
85	High prevalence of macrolide resistance: not in every country! [Comment on: Halpern et al. J Antimicrob Chemother 2005; 55: 748–57]. Journal of Antimicrobial Chemotherapy, 2005, 56, 433-434.	3.0	2
86	Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.4	2
87	Meta-analysis of bacterial resistance to macrolidesâ€"providing generalizable results: authors' response. Journal of Antimicrobial Chemotherapy, 2005, 56, 434-435.	3.0	1
88	Costs and Outcomes of Extended-Release vs. Immediate-Release Clarithromycin for Lower Respiratory Tract Infections. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 217-223.	1.6	1
89	Willingness to pay for relief of gastroesophageal reflux disease. Gastroenterology, 2001, 120, A402.	1.3	0
90	Development and validation of the treatment satisfaction questionnaire for GERD (TSQ-G). Gastroenterology, 2003, 124, A505-A506.	1.3	0

#	Article	IF	CITATIONS
91			